Targeted Medical Pharma, Inc. (TRGM)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Mar 5, 2026
Targeted Medical Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | 2010 - 2008 |
|---|---|---|---|---|---|---|
Period Ending | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | 2010 - 2008 |
| Revenue | 5.26 | 7.11 | 9.56 | 7.3 | 8.81 | Upgrade
|
| Revenue Growth (YoY) | -26.03% | -25.57% | 30.96% | -17.18% | 15.57% | Upgrade
|
| Cost of Revenue | 2.1 | 2.22 | 2.99 | 3.2 | 2.76 | Upgrade
|
| Gross Profit | 3.17 | 4.9 | 6.57 | 4.1 | 6.05 | Upgrade
|
| Selling, General & Admin | 5.04 | 7.35 | 9.77 | 10.1 | 11.44 | Upgrade
|
| Research & Development | 0.01 | 0.16 | 0.23 | 0.13 | 0.16 | Upgrade
|
| Operating Expenses | 5.06 | 7.51 | 10 | 10.23 | 11.6 | Upgrade
|
| Operating Income | -1.89 | -2.61 | -3.43 | -6.14 | -5.55 | Upgrade
|
| Interest Expense | -1.17 | -1.23 | -0.56 | -2.26 | -0.88 | Upgrade
|
| Interest & Investment Income | - | - | 0.57 | 0.06 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | 0.01 | 0.16 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.93 | -3.83 | -3.26 | -8.34 | -6.42 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.23 | Upgrade
|
| Other Unusual Items | -0.14 | - | -0.41 | -4.43 | - | Upgrade
|
| Pretax Income | -3.07 | -3.83 | -3.67 | -12.77 | -6.65 | Upgrade
|
| Income Tax Expense | - | 0.07 | 5.67 | -3.19 | -2.47 | Upgrade
|
| Earnings From Continuing Operations | -3.07 | -3.9 | -9.34 | -9.59 | -4.18 | Upgrade
|
| Minority Interest in Earnings | 0.02 | - | - | - | - | Upgrade
|
| Net Income | -3.04 | -3.9 | -9.34 | -9.59 | -4.18 | Upgrade
|
| Net Income to Common | -3.04 | -3.9 | -9.34 | -9.59 | -4.18 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 26 | 24 | 22 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 26 | 24 | 22 | 22 | Upgrade
|
| Shares Change (YoY) | 3.16% | 10.73% | 7.56% | 0.93% | 18.69% | Upgrade
|
| EPS (Basic) | -0.11 | -0.15 | -0.39 | -0.43 | -0.19 | Upgrade
|
| EPS (Diluted) | -0.11 | -0.15 | -0.39 | -0.43 | -0.19 | Upgrade
|
| Free Cash Flow | -1.28 | 0.78 | -2.08 | -2.49 | -2.67 | Upgrade
|
| Free Cash Flow Per Share | -0.05 | 0.03 | -0.09 | -0.11 | -0.12 | Upgrade
|
| Gross Margin | 60.16% | 68.84% | 68.72% | 56.12% | 68.70% | Upgrade
|
| Operating Margin | -35.93% | -36.71% | -35.94% | -84.15% | -63.00% | Upgrade
|
| Profit Margin | -57.86% | -54.76% | -97.72% | -131.38% | -47.41% | Upgrade
|
| Free Cash Flow Margin | -24.30% | 10.97% | -21.82% | -34.11% | -30.28% | Upgrade
|
| EBITDA | -1.66 | -2.21 | -3.02 | -5.7 | -5.09 | Upgrade
|
| EBITDA Margin | -31.55% | -31.06% | -31.63% | -78.18% | -57.80% | Upgrade
|
| D&A For EBITDA | 0.23 | 0.4 | 0.41 | 0.44 | 0.46 | Upgrade
|
| EBIT | -1.89 | -2.61 | -3.43 | -6.14 | -5.55 | Upgrade
|
| EBIT Margin | -35.93% | -36.71% | -35.94% | -84.15% | -63.00% | Upgrade
|
| Revenue as Reported | 5.26 | 7.11 | 9.56 | 7.3 | 8.81 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.